FibroGen Inc
FGEN
查看详细走势图
8.600USD
+0.280+3.37%
收盘 12/19, 16:00（美东）报价延迟15分钟
34.79M总市值
0.16市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.37%
5天
+2.63%
1月
+3.61%
6月
+49.57%
今年开始到现在
-35.03%
1年
-14.00%
查看详细走势图
TradingKey FibroGen Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
FibroGen Inc当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名132/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价43.00。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
FibroGen Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
43.000
目标均价
+414.35%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
FibroGen Inc亮点
亮点风险
FibroGen, Inc. is a biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia. It is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. It is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
FibroGen Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
FibroGen Inc简介
FibroGen, Inc. is a biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia. It is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. It is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
公司代码FGEN
公司FibroGen Inc
CEOWettig (Thane)
网址https://www.fibrogen.com/
常见问题
FibroGen Inc(FGEN)的当前股价是多少？
FibroGen Inc(FGEN)的当前股价是 8.600。
FibroGen Inc的股票代码是什么？
FibroGen Inc的股票代码是FGEN。
FibroGen Inc股票的52周最高点是多少？
FibroGen Inc股票的52周最高点是21.938。
FibroGen Inc股票的52周最低点是多少？
FibroGen Inc股票的52周最低点是4.850。
FibroGen Inc的市值是多少？
FibroGen Inc的市值是34.79M。
FibroGen Inc的净利润是多少？
FibroGen Inc的净利润为-47.58M。
现在FibroGen Inc(FGEN)的股票是买入、持有还是卖出？
根据分析师评级，FibroGen Inc(FGEN)的总体评级为买入，目标价格为43.000。
FibroGen Inc(FGEN)股票的每股收益（EPS TTM）是多少
FibroGen Inc(FGEN)股票的每股收益（EPS TTM）是53.442。
相关品种
